SG
MIRM icon

StepStone Group’s Mirum Pharmaceuticals MIRM Stock Holding History

StepStone Group’s Portfolio MIRM Stock Details MIRM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-4,568
Closed -$135K – 23
2023
Q4 		$135K Buy
+4,568
New +$138K 0.02% 18
2023
Q3 		– Sell
-4,179
Closed -$108K – 25
2023
Q2 		$108K Buy
+4,179
New +$111K 0.02% 22

Other funds holding MIRM

FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CCM
Cadian Capital Management New York $821M AUM 14.36% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

StepStone Group's MIRM Position: Q1 2024 in Review

StepStone Group sold out of Mirum Pharmaceuticals (MIRM) in Q1 2024, closing a stake of 4,568 shares — an estimated $135K sold.

StepStone Group first reported a position in MIRM in Q2 2023 and held it in 2 quarters. The position peaked at $135K in Q4 2023. 172 funds tracked by Wall St. Rank hold MIRM as of Q1 2024.

  • StepStone Group reported no remaining Mirum Pharmaceuticals position as of Q1 2024 after selling out during the quarter.
  • StepStone Group sold 4,568 Mirum Pharmaceuticals shares in Q1 2024, an estimated $135K.
  • StepStone Group first reported a position in Mirum Pharmaceuticals in Q2 2023 and held it in 2 quarters.
  • StepStone Group's Mirum Pharmaceuticals position peaked at $135K in Q4 2023.
  • 172 funds tracked by Wall St. Rank held Mirum Pharmaceuticals as of Q1 2024.

Based on StepStone Group's 13F filing for Q1 2024, filed 13 May 2024.